Table 1.

Phase 3, Cohort 1: Primary Efficacy End Point

Proportion of Patients With ≥1-Point Improvement in Clinical Status from Baseline to Day 22 (Critical Intention-to-Treat Patients Receiving Mechanical Ventilation at Baseline)
Primary Efficacy Endpoint	Placebo Group (n = 62)	Sarilumab 200 mg IV Group (n = 104)	Sarilumab 400 mg IV Group (n = 132)
Patients, no.(%)	22 (35.5)	45 (43.3)	57 (43.2)
95% CI	23.6–47.4	33.7–52.8	34.7–51.6
Risk difference vs placebo, %	...	7.1	7.5
95% CI	...	-8.4 to 21.7	-7.4 to 21.3
P value	...	.3707	.3261

Abbreviations: CI, confidence interval; IV, intravenous.